Assessment of avidity related to IgG subclasses in SARSCoV2 Brazilian infected patients
Sci. rep. (Nat. Publ. Group)
; 112021. tab, graf
Article
en En
| ColecionaSUS, SES-SP, SESSP-IALPROD, SES-SP, SESSP-IALACERVO
| ID: biblio-1393256
Biblioteca responsable:
BR91.2
Ubicación: BR76.1; Digital
ABSTRACT
SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefned. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specifcity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 814 and 1521 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P< 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the frst weeks of symptoms onset. Our fndings constitute the efort to clarify IgG antibodies' kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more signifcant potential for life-threatening. (AU)
Texto completo:
1
Colección:
06-national
/
BR
Base de datos:
SES-SP
/
SESSP-IALACERVO
/
SESSP-IALPROD
/
ColecionaSUS
Asunto principal:
Pacientes
/
Inmunoglobulina G
/
SARS-CoV-2
/
COVID-19
/
Afinidad de Anticuerpos
Tipo de estudio:
Prognostic_studies
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Sci. rep. (Nat. Publ. Group)
Año:
2021
Tipo del documento:
Article